Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04428-0 In the randomized, double-blind phase 3 ALTAIR trial, patients with resected colorectal cancer who became positive for circulating tumor DNA during post-adjuvant surveillance received trifluridine/tipiracil hydrochloride therapy, which did not significantly prolong disease-free survival compared with placebo.
Nature Medicine, Published online: 08 June 2026;
doi:10.1038/s41591-026-04428-0
In the randomized, double-blind phase 3 ALTAIR trial, patients with resected colorectal cancer who became positive for circulating tumor DNA during post-adjuvant surveillance received trifluridine/tipiracil hydrochloride therapy, which did not significantly prolong disease-free survival compared with placebo.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04428-0)